Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 3/20 | 0.38 |
| ▸ | CYP2B6 | P20813 | 3/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.36 |
| ▸ | UGT2B7 | P16662 | 1/20 | 0.36 |
| ▸ | OGA | O60502 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29790356 | 1.00 | CYP2A6 (0.38) | CYP2A6CYP2B6CYP3A4CYP2C19FOLH1 | |
| SCHEMBL19544649 | 0.82 | CYP2A6 (0.36) | CYP2A6CYP2B6CYP3A4CYP2C19FOLH1 | |
| SCHEMBL3513409 | 0.82 | CYP2A6 (0.36) | CYP2A6CYP2B6CYP3A4CYP2C19FOLH1 | |
| SCHEMBL25489183 | 0.82 | CYP2A6 (0.36) | CYP2A6CYP2B6CYP3A4CYP2C19FOLH1 | |
| SCHEMBL30144069 | 0.82 | CYP2A6 (0.36) | CYP2A6CYP2B6CYP3A4CYP2C19FOLH1 | |
| SCHEMBL7999672 | 0.78 | CYP11B2 (0.35) | CYP2A6CYP2B6CYP3A4CYP2C19FOLH1 | |
| SCHEMBL10104625 | 0.78 | ADRB2 (0.41) | CYP2A6CYP2B6CYP3A4CYP2C19FOLH1 | |
| SCHEMBL4342752 | 0.78 | ADRB2 (0.41) | CYP2A6CYP2B6CYP3A4CYP2C19FOLH1 | |
| SCHEMBL17000184 | 0.78 | CYP2A6 (0.34) | CYP2A6CYP2B6CYP3A4CYP2C19FOLH1 | |
| SCHEMBL29974411 | 0.78 | CYP2A6 (0.34) | CYP2A6CYP2B6CYP3A4CYP2C19FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260041671-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS INC (US) | 2026-02-12 | — | — | US | disclosed |
| US-12545684-B2 | CDK2 inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2026-02-10 | — | — | US | disclosed |
| US-12539292-B2 | BRM targeting compounds and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-02-03 | — | — | US | disclosed |
| EP-4665330-A1 | PLASMA KALLIKREIN INHIBITORS | Merck Sharp & Dohme LLC (US) | 2025-12-24 | — | — | EP | disclosed |
| EP-4537905-A2 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | Arvinas Operations, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| EP-3774789-B1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS INC (US) | 2025-03-05 | — | — | EP | disclosed |
| US-20240383902-A1 | CDK2 INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2024-11-21 | — | — | US | disclosed |
| WO-2024173196-A1 | PLASMA KALLIKREIN INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2024-08-22 | — | — | WO | disclosed |
| US-11970498-B2 | CDK2 inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2024-04-30 | — | — | US | disclosed |
| US-11932648-B2 | CDK2 inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2024-03-19 | — | — | US | disclosed |
| US-20100273764-A1 | INHIBITORS OF PI3 KINASE AND/OR MTOR | AMGEN INC. (US) | 2010-10-28 | — | — | US | disclosed |
| EP-2125794-B1 | IMIDAZOLIDINONYL AMINOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | LILLY CO ELI (US) | 2010-10-20 | — | — | EP | disclosed |
| US-20100130466-A1 | TRIAZOLYL AMINOPYRIMIDINE COMPOUNDS | ELI LILLY AND COMPANY | 2010-05-27 | — | — | US | disclosed |
| US-20100081641-A1 | IMIDAZOLIDINONYL AMINOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY | 2010-04-01 | — | — | US | disclosed |
| CN-101679396-A | Triazolylaminopyrimidine compounds | LILLY CO ELI | 2010-03-24 | — | — | CN | disclosed |
| EP-2155735-A2 | TRIAZOLYL AMINOPYRIMIDINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2010-02-24 | — | — | EP | disclosed |
| EP-2125794-A1 | IMIDAZOLIDINONYL AMINOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | Eli Lilly & Company (US) | 2009-12-02 | — | — | EP | disclosed |
| CN-101568539-A | Imidazolidinonyl aminopyrimidine compounds for the treatment of cancer | LILLY CO ELI (US) | 2009-10-28 | — | — | CN | disclosed |
| WO-2008144222-A2 | TRIAZOLYL AMINOPYRIMIDINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2008-11-27 | — | — | WO | disclosed |
| WO-2008076705-A1 | IMIDAZOLIDINONYL AMINOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY (US) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273764-A1 | INHIBITORS OF PI3 KINASE AND/OR MTOR | MTOR, PIK3CA, PIK3CD | CYP2A6 4125/4885CYP2B6 3956/4885CYP3A4 3875/4885 |
| US-11932648-B2 | CDK2 inhibitors | CDK2, CDK20, CDK2AP1 | CYP2A6 3423/4885CYP2B6 3583/4885CYP3A4 3923/4885 |
| US-12539292-B2 | BRM targeting compounds and associated methods of use | ADRM1, SUMO2, BAZ1A | CYP2A6 4194/4885CYP2B6 4571/4885CYP3A4 4848/4885 |
| US-11970498-B2 | CDK2 inhibitors | CDK2, CDK20, CDK2AP1 | CYP2A6 3423/4885CYP2B6 3583/4885CYP3A4 3923/4885 |
| US-20240383902-A1 | CDK2 INHIBITORS | CDK2, CDK20, CDK2AP1 | CYP2A6 3423/4885CYP2B6 3583/4885CYP3A4 3923/4885 |
| US-20260041671-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ADRM1, VHL, BAZ1A | CYP2A6 4179/4885CYP2B6 4598/4885CYP3A4 4783/4885 |
| US-20100081641-A1 | IMIDAZOLIDINONYL AMINOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | PLK1, AURKC, BUB1B | CYP2A6 4766/4885CYP2B6 4720/4885CYP3A4 4556/4885 |
| US-12545684-B2 | CDK2 inhibitors | CDK2, CDK4, CDK1 | CYP2A6 2207/4885CYP2B6 2273/4885CYP3A4 1837/4885 |
| US-20100130466-A1 | TRIAZOLYL AMINOPYRIMIDINE COMPOUNDS | DPYD, TP53, TYMP | CYP2A6 1744/4885CYP2B6 971/4885CYP3A4 586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.